Prothena Biosciences Inc   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: South San Francisco CA United States (2012)

Organization Overview

First Clinical Trial
2013
NCT01707264
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Clinical Trials Prothena Biosciences Inc | Prothena Biosciences Limited | Prothena Biosciences Ltd. | Prothena Therapeutics Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

neod001 (6 trials)

Drugs in Phase 2 Trials (1)

prasinezumab (2 trials)

Drugs in Phase 1 Trials (3)

prx002 (2 trials)

prx003 (2 trials)

prx004 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyloidosis (Phase 3)

Immunoglobulin Light-chain Amyloidosis (Phase 2)

Parkinson Disease (Phase 2)

Psoriasis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 5